These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 32922263)

  • 1. Pathomechanisms and Clinical Implications of Myasthenic Syndromes Exacerbated and Induced by Medical Treatments.
    Krenn M; Grisold A; Wohlfarth P; Rath J; Cetin H; Koneczny I; Zimprich F
    Front Mol Neurosci; 2020; 13():156. PubMed ID: 32922263
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Presynaptic Paraneoplastic Disorders of the Neuromuscular Junction: An Update.
    Giannoccaro MP; Avoni P; Liguori R
    Brain Sci; 2021 Aug; 11(8):. PubMed ID: 34439654
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Classification of myasthenia gravis and congenital myasthenic syndromes in dogs and cats.
    Mignan T; Targett M; Lowrie M
    J Vet Intern Med; 2020 Sep; 34(5):1707-1717. PubMed ID: 32668077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Myasthenia and the neuromuscular junction.
    Gilhus NE
    Curr Opin Neurol; 2012 Oct; 25(5):523-9. PubMed ID: 22892950
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Specific binding of collagen Q to the neuromuscular junction is exploited to cure congenital myasthenia and to explore bases of myasthenia gravis.
    Ohno K; Ito M; Kawakami Y; Krejci E; Engel AG
    Chem Biol Interact; 2013 Mar; 203(1):335-40. PubMed ID: 22981737
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Myasthenic syndromes.
    Farrugia ME
    J R Coll Physicians Edinb; 2011 Mar; 41(1):43-7; quiz 48. PubMed ID: 21365067
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Myasthenia gravis and myasthenic syndromes.
    Engel AG
    Ann Neurol; 1984 Nov; 16(5):519-34. PubMed ID: 6095730
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathogenesis of myasthenia gravis: update on disease types, models, and mechanisms.
    Phillips WD; Vincent A
    F1000Res; 2016; 5():. PubMed ID: 27408701
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Myasthenia, from the internist's point of view].
    Eymard B
    Rev Med Interne; 2014 Jul; 35(7):421-9. PubMed ID: 24112993
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efgartigimod improves muscle weakness in a mouse model for muscle-specific kinase myasthenia gravis.
    Huijbers MG; Plomp JJ; van Es IE; Fillié-Grijpma YE; Kamar-Al Majidi S; Ulrichts P; de Haard H; Hofman E; van der Maarel SM; Verschuuren JJ
    Exp Neurol; 2019 Jul; 317():133-143. PubMed ID: 30851266
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Immunologic aspects of disorders of neuromuscular transmission. 2. Experimental autoimmune myasthenia gravis and the Lambert-Eaton myasthenic syndrome].
    Andreis I; Lovnićki TJ; Beara N; Taradi M
    Lijec Vjesn; 1994; 116(5-6):158-61. PubMed ID: 7968205
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Update in the Management of Myasthenia Gravis and Lambert-Eaton Myasthenic Syndrome.
    Bodkin C; Pascuzzi RM
    Neurol Clin; 2021 Feb; 39(1):133-146. PubMed ID: 33223079
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Editorial introduction: from the structure and functions of the neuromuscular junction to the diseases].
    Takamori M
    Brain Nerve; 2011 Jul; 63(7):635-40. PubMed ID: 21747132
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autoimmune disorders of the neuromuscular junction.
    Vincent A
    Neurol India; 2008; 56(3):305-13. PubMed ID: 18974557
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Myasthenia gravis and myasthenic syndromes].
    Marouf W; Sieb JP
    Z Rheumatol; 2009 Aug; 68(6):465-70. PubMed ID: 19609783
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ANTIBODIES AND RECEPTORS: From Neuromuscular Junction to Central Nervous System.
    Vincent A
    Neuroscience; 2020 Jul; 439():48-61. PubMed ID: 32194225
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuromuscular junction disorders.
    Verschuuren J; Strijbos E; Vincent A
    Handb Clin Neurol; 2016; 133():447-66. PubMed ID: 27112691
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Muscle Is Not a Passive Target in Myasthenia Gravis.
    Vilquin JT; Bayer AC; Le Panse R; Berrih-Aknin S
    Front Neurol; 2019; 10():1343. PubMed ID: 31920954
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathological mechanisms in experimental autoimmune myasthenia gravis. II. Passive transfer of experimental autoimmune myasthenia gravis in rats with anti-acetylcholine recepotr antibodies.
    Lindstrom JM; Engel AG; Seybold ME; Lennon VA; Lambert EH
    J Exp Med; 1976 Sep; 144(3):739-53. PubMed ID: 182897
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Myasthenia Gravis With Antibodies Against Muscle Specific Kinase: An Update on Clinical Features, Pathophysiology and Treatment.
    Cao M; Koneczny I; Vincent A
    Front Mol Neurosci; 2020; 13():159. PubMed ID: 32982689
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.